GeNeuro and Servier announce successful 12-month results
GeNeuro and Servier announce successful 12-month results in neuroprotection for Phase 2b CHANGE-MS Study with GNbAC1 in Multiple Sclerosis
- Positive results on key endpoints related to neuroprotection
- Safety of GNbAC1 confirmed
- GeNeuro will hold a conference call and webcast today Monday, March 26th at 2:00 pm CEST / 8:00 am EDST, to discuss results
Diary - News
All news GeNeuro and Servier announce successful 12-month results 